Carboplatin and Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

Masters, Gregory A.

doi:10.1634/theoncologist.6-suppl_1-12

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A combination of platinum based chemotherapy (Carboplatin or Cisplatin) and Vinorelbine remains a cornerstone in first-line treatment of NSCLC. The response rate, however, is low (around 30 %) [1][2][3] and the treatment is associated with considerable toxicity [4,5].…”

Section: Introductionmentioning

confidence: 99%

The Predictive Value of Germline Polymorphisms in Patients with NSCLC

Nygaard¹,

Spindler²,

Nyhus³

et al. 2010

JCT

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in the western world, and closely related to smoking. The majority of the patients can not be offered treatment with curative intent. Palliative chemotherapy has limited effect but a considerable level of toxicity. Predictive markers are therefore urgently needed. Single Nucleotide Polymorphisms (SNPs) are stable markers of potential clinical value and the study aimed at evaluating their use in lung cancer patients given standard chemotherapy. Genomic DNA was extracted from a pre-treatment blood sample drawn from patients with advanced Non-Small Celled Lung Cancer (NSCLC), referred to palliative chemotherapy (Carboplatin and Vinorelbine) at the Department of Oncology, Vejle Hospital, between 2007 and 2010. Eighty-seven patients were included in a test cohort, and 161 patients in an independent validation cohort. A panel of 107 SNPs in the EGF, VEGF and DNA-excision repair systems was investigated. The primary endpoint was response rates (RR). Secondary endpoints were progression free survival (PFS) and overall survival (OS). SNPs with significant association to outcome in the test cohort were further tested in the validation cohort. Haplotypes were estimated and analyzed when relevant. There were no significant associations between SNPs in the EGF system or the DNA-repair system and RR, PFS or OS. In contrast, the VEGF+405, VEGF-460 and VEGF-2579, heterozygous patients had a higher response rate and longer PFS than homozygous patients. Haplotype analysis of the VEGF+405 and VEGF-460 supported our findings. These results were, however, not confirmed in the validation cohort. Although significant results regarding VEGF related SNPs, in the primary analysis, no predictive value of a broad panel of SNPs in NSCLC was found in the validation cohort, underlining the importance of independent validation of biomarker analysis

show abstract

Section: Introductionmentioning

confidence: 99%

The Predictive Value of Germline Polymorphisms in Patients with NSCLC

Nygaard¹,

Spindler²,

Nyhus³

et al. 2010

JCT

View full text Add to dashboard Cite

show abstract

“…Carboplatin in combination with vinorelbine has been explored in a number of phase II NSCLC trials. [13][14][15][16][17][18][19][20] Although generally well tolerated, doselimiting myelosuppression, as a result of overlapping hematologic toxicities, may limit on-time chemotherapy delivery and has led to studies incorporating myeloid growth factor support. 21 Pegfilgrastim is a polyethylene glycol modified form of filgrastim designed to have a decreased plasma clearance allowing for longer half-life and a reduced dosing schedule.…”

mentioning

confidence: 99%

A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer

Riedel

Andrews

Garst

et al. 2007

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Gregory Masters discussed the potential benefit of substituting carboplatin for cisplatin in combination with vinorelbine [10]. In a phase I/II study in which the two drugs were given on days 1 and 8 every three weeks, little significant hematologic and nonhematologic toxicity was observed [11].…”

mentioning

confidence: 99%